Primary primitive neuroectodermal tumor of the breast: Analysis of clinical outcomes of twenty‐one patients
- 23 May 2020
- journal article
- editorial
- Published by Hindawi Limited in The Breast Journal
- Vol. 26 (9), 1893-1894
- https://doi.org/10.1111/tbj.13894
Abstract
Click on the article title to read more.Keywords
Funding Information
- Conquer Cancer Foundation (ASCO-LIFe award)
This publication has 6 references indexed in Scilit:
- Clinical and Pathological Features of Primary Neuroectodermal Tumor/Ewing Sarcoma of the KidneyUrology, 2013
- Substitution of cisplatin for etoposide in 2 of 3 induction cycles of CAV/IE with subsequent irinotecan and vincristine for relapse in adults with Ewing sarcoma (ES) and primitive neuroectodermal tumor (PNET).Journal of Clinical Oncology, 2012
- Primitive neuroectodermal tumor of the breastEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2008
- High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk ewing sarcoma family tumorsCancer, 2006
- Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of BoneThe New England Journal of Medicine, 2003
- Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities.Journal of Clinical Oncology, 1997